High Ground Investment Management LLP Makes New $45.65 Million Investment in Humana Inc. (NYSE:HUM)

High Ground Investment Management LLP bought a new position in Humana Inc. (NYSE:HUM – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 89,135 shares of the insurance provider’s stock, valued at approximately $45,654,000. Humana accounts for approximately 43.1% of High Ground Investment Management LLP’s holdings, making the stock its largest position. High Ground Investment Management LLP owned 0.07% of Humana as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Arlington Partners LLC acquired a new position in shares of Humana during the fourth quarter valued at $29,000. WFA of San Diego LLC acquired a new position in shares of Humana during the fourth quarter valued at $33,000. U.S. Capital Wealth Advisors LLC acquired a new position in shares of Humana during the fourth quarter valued at $35,000. SJS Investment Consulting Inc. increased its holdings in shares of Humana by 1,257.1% during the fourth quarter. SJS Investment Consulting Inc. now owns 95 shares of the insurance provider’s stock valued at $49,000 after purchasing an additional 88 shares during the period. Finally, Affiance Financial LLC bought a new position in Humana during the fourth quarter valued at about $50,000. 93.38% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on HUM shares. Truist Financial decreased their target price on Humana from $580.00 to $560.00 and set a “hold” rating for the company in a research note on Tuesday, February 7th. TheStreet cut Humana from a “b” rating to a “c+” rating in a research note on Wednesday, February 1st. Deutsche Bank Aktiengesellschaft decreased their target price on Humana from $575.00 to $562.00 and set a “buy” rating for the company in a research note on Tuesday, February 28th. StockNews.com raised Humana from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Finally, UBS Group decreased their target price on Humana from $645.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, February 2nd. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $594.12.

Humana Stock Up 0.2 %

Shares of HUM traded up $1.17 during midday trading on Friday, reaching $495.55. 1,962,747 shares of the stock were exchanged, compared to its average volume of 851,645. The firm has a 50 day simple moving average of $494.78 and a 200-day simple moving average of $507.54. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59. Humana Inc. has a 12-month low of $410.87 and a 12-month high of $571.30. The company has a market cap of $61.93 billion, a price-to-earnings ratio of 22.48, a P/E/G ratio of 1.24 and a beta of 0.72.

Humana (NYSE:HUM – Get Rating) last issued its quarterly earnings data on Wednesday, February 1st. The insurance provider reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.16. Humana had a return on equity of 20.50% and a net margin of 3.02%. The business had revenue of $22.44 billion for the quarter, compared to the consensus estimate of $22.45 billion. During the same period last year, the business earned $1.24 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Research analysts forecast that Humana Inc. will post 28.05 EPS for the current year.

Humana Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 28th. Investors of record on Friday, March 31st will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.71%. This is an increase from Humana’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Thursday, March 30th. Humana’s dividend payout ratio (DPR) is presently 14.29%.

Insider Activity at Humana

In related news, CEO Bruce D. Broussard sold 17,575 shares of the firm’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $505.85, for a total value of $8,890,313.75. Following the transaction, the chief executive officer now directly owns 70,040 shares of the company’s stock, valued at approximately $35,429,734. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Humana news, CEO Bruce D. Broussard sold 17,575 shares of the firm’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $505.85, for a total value of $8,890,313.75. Following the sale, the chief executive officer now owns 70,040 shares of the company’s stock, valued at approximately $35,429,734. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David A. Jr/Ky Jones sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $501.72, for a total value of $7,525,800.00. Following the completion of the sale, the director now directly owns 42,028 shares in the company, valued at approximately $21,086,288.16. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,623 shares of company stock valued at $17,456,436. Corporate insiders own 0.39% of the company’s stock.

Humana Company Profile

(Get Rating)

Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.